Large-scale whole-genome resequencing unravels the domestication history of Cannabis sativa.

Cannabis sativa has long been an important source of fiber extracted from hemp and both medicinal and recreational drugs based on cannabinoid compounds. Here, we investigated its poorly known domestication history using whole-genome resequencing of 110 accessions from worldwide origins. We show that C. sativa was first domesticated in early Neolithic times in East Asia and that all current hemp and drug cultivars diverged from an ancestral gene pool currently represented by feral plants and landraces in China. We identified candidate genes associated with traits differentiating hemp and drug cultivars, including branching pattern and cellulose/lignin biosynthesis. We also found evidence for loss of function of genes involved in the synthesis of the two major biochemically competing cannabinoids during selection for increased fiber production or psychoactive properties. Our results provide a unique global view of the domestication of C. sativa and offer valuable genomic resources for ongoing functional and molecular breeding research

Biogenic fabrication of iron oxide nanoparticles from Leptolyngbya sp. L-2 and multiple in vitro pharmacogenetic properties

Metallic nanoparticles have received a significant amount of reflection over a period of time, attributed to their electronic, specific surface area, and surface atom properties. The biogenic synthesis of iron oxide nanoparticles (FeONPs) is demonstrated in this study. The green synthesis of metallic nanoparticles (NPs) is acquiring considerable attention due to its environmental and economic superiorities over other methods. Leptolyngbya sp. L-2 extract was employed as a reducing agent, and iron chloride hexahydrate (FeCl3·6H2O) was used as a substrate for the biogenic synthesis of FeONPs. Different spectral methods were used for the characterization of the biosynthesized FeONPs, ultraviolet-visible (UV-Vis) spectroscopy gave a surface plasmon resonance (SPR) peak of FeONPs at 300 nm; Fourier transform infrared (FTIR) spectral analysis was conducted to identify the functional groups responsible for both the stability and synthesis of FeONPs. The morphology of the FeONPs was investigated using scanning electron microscopy (SEM), which shows a nearly spherical shape, and an X-ray diffraction (XRD) study demonstrated their crystalline nature with a calculated crystallinity size of 23 nm. The zeta potential (ZP) and dynamic light scattering (DLS) measurements of FeONPs revealed values of −8.50 mV, suggesting appropriate physical stability. Comprehensive in-vitro pharmacogenetic properties revealed that FeONPs have significant therapeutic potential. FeONPs have been reported to have potential antibacterial and antifungal properties. Dose-dependent cytotoxic activity was shown against Leishmania tropica promastigotes (IC50: 10.73 µg/mL) and amastigotes (IC50: 16.98 µg/mL) using various concentrations of FeONPs. The cytotoxic potential was also investigated using brine shrimps, and their IC50 value was determined to be 34.19 µg/mL. FeONPs showed significant antioxidant results (DPPH: 54.7%, TRP: 49.2%, TAC: 44.5%), protein kinase (IC50: 96.23 µg/mL), and alpha amylase (IC50: 3745 µg/mL). The biosafety of FeONPs was validated by biocompatibility tests using macrophages (IC50: 918.1 µg/mL) and red blood cells (IC50: 2921 µg/mL). In conclusion, biogenic FeONPs have shown potential biomedical properties and should be the focus of more studies to increase their nano-pharmacological significance for biological applications

Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at √s=0.9 and 2.36 TeV

Measurements of inclusive charged-hadron transverse-momentum and pseudorapidity distributions are presented for proton-proton collisions at root s = 0.9 and 2.36 TeV. The data were collected with the CMS detector during the LHC commissioning in December 2009. For non-single-diffractive interactions, the average charged-hadron transverse momentum is measured to be 0.46 +/- 0.01 (stat.) +/- 0.01 (syst.) GeV/c at 0.9 TeV and 0.50 +/- 0.01 (stat.) +/- 0.01 (syst.) GeV/c at 2.36 TeV, for pseudorapidities between -2.4 and +2.4. At these energies, the measured pseudorapidity densities in the central region, dN(ch)/d eta vertical bar(vertical bar eta vertical bar and pp collisions. The results at 2.36 TeV represent the highest-energy measurements at a particle collider to date

Evaluation of passive polarized stereoscopic 3D display for visual & mental fatigues

Visual and mental fatigues induced by active shutter stereoscopic 3D (S3D) display have been reported using event-related brain potentials (ERP). An important question, that is whether such effects (visual &amp; mental fatigues) can be found in passive polarized S3D display, is answered here. Sixty-eight healthy participants are divided into 2D and S3D groups and subjected to an oddball paradigm after being exposed to S3D videos with passive polarized display or 2D display. The age and fluid intelligence ability of the participants are controlled between the groups. ERP results do not show any significant differences between S3D and 2D groups to find the aftereffects of S3D in terms of visual and mental fatigues. Hence, we conclude that passive polarized S3D display technology may not induce visual and/or mental fatigue which may increase the cognitive load and suppress the ERP components.</p

Classification of EEG signals based on pattern recognition approach

Feature extraction is an important step in the process of electroencephalogram (EEG) signal classification. The authors propose a “pattern recognition” approach that discriminates EEG signals recorded during different cognitive conditions. Wavelet based feature extraction such as, multi-resolution decompositions into detailed and approximate coefficients as well as relative wavelet energy were computed. Extracted relative wavelet energy features were normalized to zero mean and unit variance and then optimized using Fisher’s discriminant ratio (FDR) and principal component analysis (PCA). A high density EEG dataset validated the proposed method (128-channels) by identifying two classifications: (1) EEG signals recorded during complex cognitive tasks using Raven’s Advance Progressive Metric (RAPM) test; (2) EEG signals recorded during a baseline task (eyes open). Classifiers such as, K-nearest neighbors (KNN), Support VectorMachine (SVM),Multi-layer Perceptron (MLP), and Naïve Bayes (NB) were then employed. Outcomes yielded 99.11% accuracy via SVM classifier for coefficient approximations (A5) of low frequencies ranging from 0 to 3.90Hz. Accuracy rates for detailed coefficients were 98.57 and 98.39% for SVM and KNN, respectively; and for detailed coefficients (D5) deriving from the sub-band range (3.90–7.81Hz). Accuracy rates for MLP and NB classifiers were comparable at 97.11–89.63% and 91.60–81.07% for A5 and D5 coefficients, respectively. In addition, the proposed approach was also applied on public dataset for classification of two cognitive tasks and achieved comparable classification results, i.e., 93.33% accuracy with KNN. The proposed scheme yielded significantly higher classification performances using machine learning classifiers compared to extant quantitative feature extraction. These results suggest the proposed feature extraction method reliably classifies EEG signals recorded during cognitive tasks with a higher degree of accuracy.</p

Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry

Aims: Hypertensive disorders occur in women with peripartum cardiomyopathy (PPCM). How often hypertensive disorders co-exist, and to what extent they impact outcomes, is less clear. We describe differences in phenotype and outcomes in women with PPCM with and without hypertensive disorders during pregnancy. Methods: The European Society of Cardiology PPCM Registry enrolled women with PPCM from 2012-2018. Three groups were examined: 1) women without hypertension (‘PPCM-noHTN’); 2) women with hypertension but without pre-eclampsia (‘PPCM-HTN’); 3) women with pre-eclampsia (‘PPCM-PE’). Maternal (6-month) and neonatal outcomes were compared. Results: Of 735 women included, 452 (61.5%) had PPCM-noHTN, 99 (13.5%) had PPCM-HTN and 184 (25.0%) had PPCM-PE. Compared to women with PPCM-noHTN, women with PPCM-PE had more severe symptoms (NYHA IV in 44.4% and 29.9%, p&lt;0.001), more frequent signs of heart failure (pulmonary rales in 70.7% and 55.4%, p=0.002), higher baseline LVEF (32.7% and 30.7%, p=0.005) and smaller left ventricular end diastolic diameter (57.4mm [±6.7] and 59.8mm [±8.1], p&lt;0.001). There were no differences in the frequencies of death from any cause, re-hospitalization for any cause, stroke, or thromboembolic events. Compared to women with PPCM-noHTN, women with PPCM-PE had a greater likelihood of left ventricular recovery (LVEF≥50%) (adjusted OR 2.08 95% CI 1.21-3.57) and an adverse neonatal outcome (composite of termination, miscarriage, low birth weight or neonatal death) (adjusted OR 2.84 95% CI 1.66-4.87). Conclusion: Differences exist in phenotype, recovery of cardiac function and neonatal outcomes according to hypertensive status in women with PPCM